
-
Former boxing world champion Hatton 'excited for the future' before death: family
-
Stocks, dollar calm before expected US rate cut
-
After mass Nepal jailbreak, some prisoners surrender
-
Poison killed Putin critic Navalny, wife says
-
Australia coach expects Cummins to play 'key part' in Ashes
-
Hong Kong leader plans to fast-track border mega-project
-
Ben & Jerry's co-founder quits, says independence 'gone'
-
Erasmus keeps faith with Springbok squad after record All Blacks win
-
Hong Kong leader unveils plan to boost growth with border mega-project, AI push
-
Israel says opening new route for Gazans fleeing embattled city
-
New Zealand's historic athletics worlds a decade in the making
-
Trump to get royal treatment on UK state visit
-
Benfica sack Lage after shock defeat, Mourinho next?
-
Israel says to open new route for Gazans fleeing embattled city
-
Nestle share price slips as chairman follows CEO out the door
-
German suspect in Madeleine McCann case freed from prison
-
US tennis star Townsend apologises for 'crazy' Chinese food post
-
Peru evacuates 1,600 tourists from Machu Picchu amid protest
-
Nepal mourns its dead after anti-corruption protests
-
UK inflation stable ahead of central bank rate call
-
India checks Maoist rebel offer of suspending armed struggle
-
Israel to open new route for Gazans fleeing besieged city
-
Lower shipments to US, China weigh on Singapore August exports
-
Inside the hunt for the suspect in Charlie Kirk's killing
-
Junta accused of coveting power in crucial Guinea referendum
-
TV writer Hagai Levi: boycott risks hitting Israel's critical voices
-
Sri Lanka to ban predatory pet fish to protect ecosystems
-
'Genius' De Bruyne leads Napoli in emotional return to Man City
-
World number one Sabalenka out of China Open with injury
-
Estimated 16,500 climate change deaths during Europe summer: study
-
'Fifa' successor 'FC 26' polishes the beautiful game
-
Park Chan-wook's murder comedy to open Asia's biggest film festival
-
India's gaming fans eye illegal sites after gambling ban
-
EU business lobby head says China rare earths snag persists
-
Botox under burqas: Cosmetic surgery in vogue in Afghanistan
-
Asian stocks swing as traders bide time ahead of US rate decision
-
Australia, Papua New Guinea delay mutual defence treaty
-
PGA's 2026 opener will not be played at drought-hit Kapalua
-
Toucans, tortoises saved in major Brazil trafficking bust
-
Britain rolls out royal red carpet for Trump's state visit
-
US Fed set for first rate cut of 2025 as Trump pressure looms
-
Broadway jeering Caesars Times Square casino bet
-
Rojas, McLaughlin-Levrone go for gold at world champs
-
Colombian FARC leaders ordered to make reparations for over 21,000 kidnappings
-
Live Ventures' Diverse Portfolio Is Its Ultimate Superpower (NASDAQ:LIVE)
-
Electrovaya Commences Drawdown on Export-Import Bank of the United States ("EXIM") Loan Facility and Provides a Business Update
-
Empire AV Services & Installations LLC Wins 2025 Consumer Choice Award for Excellence in AV Services in Dallas-Fort Worth
-
Nextech3D.ai Launches Event Ticketing Software Solutions With Blockchain Ticketing Launching in Q4
-
Intelligent Protection Management Corp. Enters Into AI Reseller Agreement with MindsDB
-
Heron Hospitality Acquires Atlantis Lodge, Preserving Legacy While Expanding Coastal Vision
CMSC | 0.29% | 24.39 | $ | |
RYCEF | -0.06% | 15.64 | $ | |
AZN | -0.63% | 77.56 | $ | |
NGG | -1.04% | 70.88 | $ | |
GSK | -0.62% | 40.05 | $ | |
SCS | 0.06% | 16.88 | $ | |
CMSD | 0.04% | 24.46 | $ | |
RELX | -0.36% | 46.69 | $ | |
RBGPF | 0% | 77.27 | $ | |
RIO | -0.44% | 63.44 | $ | |
VOD | -0.34% | 11.77 | $ | |
BCC | -3.31% | 82.39 | $ | |
BTI | -0.43% | 55.79 | $ | |
BCE | -1.11% | 23.43 | $ | |
JRI | -1.01% | 13.92 | $ | |
BP | 0.64% | 34.43 | $ |

US panel weighs authorizing Covid vaccines for youngest children
After months of anxious wait for some parents, a panel of experts convened by the US Food and Drug Administration will meet Wednesday to weigh recommending Covid vaccines for the nation's youngest children.
Children under five are the only age group not yet eligible for Covid immunization in the United States and most other countries. If, as expected, panelists vote in favor of greenlighting the Pfizer and Moderna vaccines, formal authorizations should follow quickly, with the first shots in arms expected by next week.
Ahead of the meeting, the FDA posted its independent analyses of the two drugs, deeming both safe and effective. It also said there was a pressing unmet need to inoculate children in the age group since their rates of hospitalization and death "are higher than among children and adolescents 5-17 years of age."
Both vaccines are based on messenger RNA technology, which delivers genetic code for the coronavirus spike protein to human cells, training the immune system to be ready for when it encounters the real virus.
Pfizer is seeking authorization for three doses at three micrograms given to ages six months through four years, while Moderna has asked for the FDA to approve its vaccine as two doses of a higher 30 micrograms, for ages six months through five years.
They were tested in trials of thousands of children where they were found to have similar levels of mild effects to older age groups and triggered similar levels of antibodies.
Efficacy against infection was higher for Pfizer, with the company placing it at 80 percent compared to Moderna's estimates of 51 percent in the six-month-old to age two group and 37 percent in the two to five years age group.
But the figures are provisional and Moderna is studying adding a third dose later that may increase its figures.
There are some 20 million US children aged four years and under. If the FDA-appointed experts recommend the two vaccines, then the matter will go to another committee convened by the Centers for Disease Control and Prevention for a final say.
White House officials last week said the rollout of millions of shots at pharmacies and doctors' offices could begin as soon as June 21, following the Juneteenth holiday on June 20.
Of the total US Covid deaths, 480 have come in children under five, according to the latest official data.
Obesity, neurological disorders and asthma are associated with increased risk of severe disease, "however, a majority of children hospitalized for Covid-19 have no underlying medical conditions," the FDA said in a document.
Children can also go on to contract multisystem inflammatory syndrome in children (MIS-C), a rare but serious post-viral condition.
Data on long Covid in children is sparse, but the FDA's document cited a national survey in the United Kingdom which found that "among children ages two to 11 years who tested positive for COVID-19, 7.2 percent reported continued symptoms at 12 weeks."
L.Durand--AMWN